Recent Press Releases

AstraZeneca Urges Increase in FDA Funding

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) urged the Obama Administration to increase funding for the Food and Drug Administration’s fiscal year 2012 budget by 20 percent to help the

The Deal Names Abbott Top Dealmaker for Third Consecutive Year

Awards Recognize Industry-Leading Companies That Demonstrate Effective Strategic Use of Mergers and Acquisitions Over Past Three YearsABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ -- The Deal

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes PARIS, September 20, 2010 /PRNewswire/ -- - Findings Presented at

Abbott Introduces Sports Nutrition Performance Beverage - EAS Peak™ With New P3™ Technology

EAS Peak Helps Fitness Enthusiasts Sustain Energy, Increase Workout Capacity and Reduce Muscle Breakdown - Creating a New Category of Performance BeveragesABBOTT PARK, Ill., Sept. 20 /PRNewswire/ --

FDA reviewing preliminary safety information on Actos (pioglitazone)

FDA reviewing preliminary safety information on Actos (pioglitazone) The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone),

Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis

Positive benefit-risk profile of laquinimod sustained in Phase II extension study52 percent reduction (p=0.0006) in mean number of gadolinium-enhancing (GdE) T1 lesionsResults from pivotal Phase III

Genentech Provides Update on Avastin for Advanced Breast Cancer

Genentech Provides Update on Avastin for Advanced Breast Cancer-- FDA Extends Review Period for Supplemental Biologics License Applications -- SOUTH SAN FRANCISCO, Calif., Sep 17, 2010 (BUSINESS

Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges

Researchers say human traits of 'warmth and competence' hold key to brand loyaltyPHILADELPHIA, Sept. 20 /PRNewswire/ -- Despite Tylenol's product recalls and plant closure, the company still outpaces

Roche Launches New Initiative - 'Roche Goes to Town'

Designed to Build Deeper Community Connection and Stimulate Local Business GrowthNUTLEY, N.J., Sept. 20 /PRNewswire/ -- In an effort to stimulate local business activity and encourage its employees

UBS Global Life Sciences Conference Opens in New York

NEW YORK--(BUSINESS WIRE)-- The UBS Global Life Sciences Conference opens today at the Grand Hyatt in New York City and runs through Wednesday, September 22. The annual UBS Global Life Sciences

Kite Pharma Appoints Dr. Gloria Lee Chief Medical Officer

LOS ANGELES--(BUSINESS WIRE)-- Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Gloria Lee, M.D.,

Celera Signs Agreement with Abbott for Distribution of CE-marked KIF6 Test to Identify Patients at Risk of Coronary Heart

ALAMEDA, Calif. & DES PLAINES, Ill.--(BUSINESS WIRE)-- Celera Corporation (NASDAQ:CRA) and Abbott (NYSE:ABT) today announced that they have signed an exclusive distribution agreement to market

24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepirid

STOCKHOLM, September 20, 2010 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY)(http://www.bms.com) and AstraZeneca (NYSE: AZN)(http://www.astrazeneca-us.com) today announced results

24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glim

STOCKHOLM--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated

Nektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference

SAN CARLOS, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2010

Genentech Provides Update on Avastin for Advanced Breast Cancer

-- FDA Extends Review Period for Supplemental Biologics License Applications -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX:

AAM Calls for Lower Health Care Costs, Faster Generic Drug Approvals

AAM Calls for Lower Health Care Costs, Faster Generic Drug ApprovalsROCKVILLE, MD, Sept. 17, 2010 - The Alliance for Affordable Medicine (AAM, formerly known as the Coalition for a Competitive

HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada

Agreement follows FDA approval of ella® in the U.S., where Watson will market the productPARIS and MORRISTOWN, N.J., Sept. 17 /PRNewswire-FirstCall/ -- HRA Pharma, a privately-held, European

Teva to Present at the UBS Global Life Sciences Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the UBS Global Life Sciences Conference with William Marth, President & CEO, Teva

Chairman Towns Announces Hearing to Examine Johnson & Johnson Recalls

Chairman Towns Announces Hearing to Examine Johnson & Johnson Recalls Chairman Towns Announces Johnson & Johnson HearingAnnounces second J&J hearing on circumstances surrounding